FIG 2.

Moxifloxacin therapy. (A) Moxifloxacin efficacy in previously immunized mice. Mice were given HBSS (diamonds) or immunized with glanders vaccine (HKBp) (triangles) followed by B. mallei aerosol challenge (ATCC 23344; 1.5 LD₅₀). Immunized mice were given moxifloxacin therapy (Moxi) beginning 3 days after challenge for durations of 3 (small squares) or 5 (large squares) days. Note that line breaks (//) indicate changes in the scale of the x axis. (B) Moxifloxacin efficacy in immunized and unimmunized mice. Mice were given HBSS (diamonds) or immunized with glanders vaccine (HKBp) (triangles) followed by B. mallei aerosol challenge (ATCC 23344; 3 LD₅₀). Moxifloxacin therapy (Moxi) was initiated 5 days after challenge for durations of 5 (unimmunized mice, small circles; immunized mice, small squares) or 10 (unimmunized mice, large circles; immunized mice, large squares) days. Line breaks (//) indicate changes in the scale of the x axis. (C) Moxifloxacin efficacy in immunized and unimmunized mice. Mice were given HBSS (diamonds) or immunized with glanders vaccine (HKBp) (triangles) followed by B. mallei aerosol challenge (B. mallei FMH23344; 1 LD₅₀). Moxifloxacin therapy (Moxi) was initiated 5 days after challenge for durations of 5 (unimmunized mice, small circles; immunized mice, small squares) or 10 (unimmunized mice, large circles; immunized mice, large squares) days. Note that line breaks (//) indicate changes in the scale of the x axis. (D) Lack of residual infection after moxifloxacin therapy. Mice were given HBSS or immunized with glanders vaccine (HKBp) followed by B. mallei aerosol challenge (B. mallei FMH23344; 1 LD₅₀). Moxifloxacin therapy (Moxi) was initiated 5 days (+ 5d) after challenge for durations of 5 or 10 days.